A glimpse into the future: mapping global research trends in immunotherapy for rare tumors [0.03%]
一览展望：绘制罕见肿瘤免疫治疗全球研究趋势地图
Guo Zhao,Yuning Wang,Shuhang Wang et al.
Guo Zhao et al.
The prognostic role of circulating tumor DNA across breast cancer molecular subtypes: A systematic review and meta-analysis [0.03%]
循环肿瘤DNA在不同分子亚型乳腺癌中的预后作用：系统评价和 Meta 分析
Nana Guo,Qingxin Zhou,Meng Zhang et al.
Nana Guo et al.
Objective: Circulating tumor DNA (ctDNA) is increasingly being used as a potential prognostic biomarker in cancer patients. We aimed to assess the prognostic value of ctDNA in different subtypes of breast cancer patients ...
Concordance between four PD-L1 immunohistochemical assays and 22C3 pharmDx assay in esophageal squamous cell carcinoma in a multicenter study [0.03%]
四项PD-L1免疫组化检测与22C3 PharmDx试剂盒在中国多家医院食管鳞癌患者中的一致性研究
Liyan Xue,Yuan Li,Lili Jiang et al.
Liyan Xue et al.
Background: The prediction of response to immunotherapy mostly depends on the programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) status, and the 22C3 pharmDx assay has been approved in esophageal squamous cell c...
Lin Li,Wenqin Xie,Li Zhan et al.
Lin Li et al.
The evolutionary dynamics of cancer, characterized by its profound heterogeneity, demand sophisticated tools for a holistic understanding. This review delves into tumor phylogenetics, an essential approach bridging evolutionary biology with...
Clinical, pathological, and adjuvant chemotherapy use differences among microsatellite unstable and microsatellite stable colon cancers [0.03%]
微卫星不稳定型和微卫星稳定型结肠癌的临床、病理及辅助化疗使用差异
Baqir Hasan Jafry,Munir Hassan Buhaya,Allante Milsap et al.
Baqir Hasan Jafry et al.
Background: Colon cancers are categorized into mismatch repair deficient/microsatellite unstable (MSI-H) and mismatch repair proficient/microsatellite stable (MSS) cancers. This study aims to compare the disease character...
Dynamic bTMB combined with residual ctDNA improves survival prediction in locally advanced NSCLC patients with chemoradiotherapy and consolidation immunotherapy [0.03%]
动态bTMB联合残留ctDNA可改善不可切除局晚期NSCLC放化疗序贯免疫巩固治疗患者的生存预测能力
Yu Wang,Wenqing Wang,Tao Zhang et al.
Yu Wang et al.
Background: Liquid biopsy-based biomarkers, including circulating tumor DNA (ctDNA) and blood tumor mutational burden (bTMB), are recognized as promising predictors of prognoses and responses to immune checkpoint inhibito...
Comparative study of cancer profiles between 2020 and 2022 using global cancer statistics (GLOBOCAN) [0.03%]
利用全球癌症统计（GLOBOCAN）比较2020年和2022年的癌症概况研究报告
Wei Cao,Kang Qin,Feng Li et al.
Wei Cao et al.
Background: The International Agency for Research on Cancer (IARC) released the latest estimates of the global burden of cancer. We present a comparison of cancer profiles between 2020 and 2022, leveraging data from the G...
Application of Survival Quilts for prognosis prediction of gastrectomy patients based on the Surveillance, Epidemiology, and End Results database and China National Cancer Center Gastric Cancer database [0.03%]
基于SEER数据库和中国国家癌症中心胃癌数据库的生存被子在胃切除患者预后预测中的应用研究
Lulu Zhao,Penghui Niu,Wanqing Wang et al.
Lulu Zhao et al.
Objective: Accurate prognosis prediction is critical for individualized-therapy making of gastric cancer patients. We aimed to develop and test 6-month, 1-, 2-, 3-, 5-, and 10-year overall survival (OS) and cancer-specifi...
Nowcasting and forecasting global aging and cancer burden: analysis of data from the GLOBOCAN and Global Burden of Disease Study [0.03%]
全球人口老龄化和癌症负担的现测与预测：GLOBOCAN和全球疾病负担研究数据的分析
Lixi Li,Tianhao Shan,Di Zhang et al.
Lixi Li et al.
Objective: To analyze the impact of global population aging on cancer epidemiology, with a focus on the incidence and mortality rates among individuals aged 60 years and above. ...
Cancer survival statistics in China 2019-2021: a multicenter, population-based study [0.03%]
中国2019-2021年癌症生存统计分析：多中心人群为基础的队列研究
Hongmei Zeng,Rongshou Zheng,Kexin Sun et al.
Hongmei Zeng et al.
Background: A milestone goal of the Healthy China Program (2019-2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated sur...